We recently published a list of Jim Cramer’s Thoughts on These 12 Stocks. In this article, we are going to take a look at ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has initiated the human trial of ARO-ALK7, a novel RNA interference (RNAi) ...

There are pulmonary, muscular, and complement-mediated disease programs - seven in total - at the Phase 1 stage, and although Arrowhead's TrIM platform has churned out some viable commercial ...